Skip to content

Insight

Resource Library

Tap into Gubra’s vast production of publications, webinars, videos and posters to get the latest knowledge and insights within our focus areas: diabetes, obesity, NASH and gastrointestinal diseases.

Filters
Search
Resource type
Category
Sort result

 

FDA approved Madrigal’s Resmetirom (Rezdiffra®) as first drug treatment for MASH. What now?

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top